Phaseline

Companies › DIGMBIO

DIGMBIO: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DM5167
PARP-1 inhibitor
PARP1Phase 1Advanced Breast CancerJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07101601DM5167Phase 1Advanced Breast CancerOncologyJan 2027

Targets

PARP1 (1)

Companies with the same targets

AstraZeneca Eikon Therapeutics Haisco Pharmaceutical Group Hangzhou SynRx Therapeutics Biomedical Technology Merck & Co. (MSD) Nerviano Medical Sciences Pfizer Johnson & Johnson (Janssen) Jiangsu Hansoh Pharmaceutical Chia Tai Tianqing Pharmaceutical Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.